Kelun Wins World’s First TROP2 ADC Approval In Lung Cancer

Merck/Kelun and AstraZeneca/Daiichi Sankyo are locked in a race to win lung cancer labels for their TROP2 ADCs. (Shutterstock)

More from Clinical Trials

More from Focus On Asia